These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1347 related items for PubMed ID: 31011254

  • 1. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ.
    World J Gastroenterol; 2019 Apr 14; 25(14):1684-1696. PubMed ID: 31011254
    [Abstract] [Full Text] [Related]

  • 2. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H.
    Med Mol Morphol; 2017 Dec 14; 50(4):185-194. PubMed ID: 28936553
    [Abstract] [Full Text] [Related]

  • 3. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
    Yamashita S, Abe H, Kunita A, Yamashita H, Seto Y, Ushiku T.
    Histopathology; 2021 Feb 14; 78(3):381-391. PubMed ID: 32767778
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S, Miyoshi H, Nakashima K, Shimono J, Hashiguchi T, Mitsuoka M, Takamori S, Akagi Y, Ohshima K.
    Clin Cancer Res; 2016 Sep 15; 22(18):4727-34. PubMed ID: 27166394
    [Abstract] [Full Text] [Related]

  • 5. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM, Helal DS, Sabry NM, Abo El-Nasr M.
    J Egypt Natl Canc Inst; 2018 Dec 15; 30(4):125-131. PubMed ID: 30337185
    [Abstract] [Full Text] [Related]

  • 6. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F, Brüwer K, Altendorf-Hofmann A, Auernhammer CJ, Spitzweg C, Westphalen CB, Boeck S, Schubert-Fritschle G, Werner J, Heinemann V, Kirchner T, Angele M, Knösel T.
    Endocr Relat Cancer; 2019 Mar 01; 26(3):293-301. PubMed ID: 30608901
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H, Li Z, Dong B, Sun W, Yang X, Liu R, Zhou L, Huang X, Jia L, Lin D.
    Diagn Pathol; 2018 May 22; 13(1):30. PubMed ID: 29789013
    [Abstract] [Full Text] [Related]

  • 8. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.
    Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M.
    Sci Rep; 2018 Sep 03; 8(1):13166. PubMed ID: 30177687
    [Abstract] [Full Text] [Related]

  • 9. PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
    Tai H, Yang Q, Wu Z, Sun S, Cao R, Xi Y, Zhao R, Zhang M, Zhang Z, Xu C.
    J Immunol Res; 2018 Sep 03; 2018():9485285. PubMed ID: 29854854
    [Abstract] [Full Text] [Related]

  • 10. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
    Oktay E, Yalcin GD, Ekmekci S, Kahraman DS, Yalcin A, Degirmenci M, Dirican A, Altin Z, Ozdemir O, Surmeli Z, Diniz G, Ayhan S, Bulut G, Erdogan A, Uslu R.
    J BUON; 2019 Sep 03; 24(2):779-790. PubMed ID: 31128036
    [Abstract] [Full Text] [Related]

  • 11. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P, Xiao Q, Zhou B, Dai Z, Kang Y.
    World Neurosurg; 2019 Sep 03; 129():e240-e254. PubMed ID: 31128313
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS.
    Oncotarget; 2017 Apr 18; 8(16):26356-26367. PubMed ID: 28412752
    [Abstract] [Full Text] [Related]

  • 13. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P, Driver B, Morales-Rosado JA, Deavers M, Tacha D, Bernicker E, Cagle PT, Miller RA.
    Arch Pathol Lab Med; 2018 Nov 18; 142(11):1388-1393. PubMed ID: 29431467
    [Abstract] [Full Text] [Related]

  • 14. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A.
    Neuropathology; 2018 Apr 18; 38(2):125-134. PubMed ID: 29067721
    [Abstract] [Full Text] [Related]

  • 15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.
    Lancet Oncol; 2018 Sep 18; 19(9):1180-1191. PubMed ID: 30120041
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer.
    Wang Q, Lou W, Di W, Wu X.
    Int Immunopharmacol; 2017 Nov 18; 52():7-14. PubMed ID: 28846888
    [Abstract] [Full Text] [Related]

  • 17. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L, Wang XI, Ding J, Sun Q, Zhang S.
    Ann Diagn Pathol; 2019 Jun 18; 40():143-151. PubMed ID: 31096176
    [Abstract] [Full Text] [Related]

  • 18. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M.
    Oncotarget; 2017 Jul 18; 8(29):46756-46768. PubMed ID: 28657901
    [Abstract] [Full Text] [Related]

  • 19. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, Lee KL, Kim W, Park JH, Kim KH, Kim JS, Choi IS, Han DS, Ahn HS, Heo SC.
    Diagn Pathol; 2020 Jun 04; 15(1):69. PubMed ID: 32498695
    [Abstract] [Full Text] [Related]

  • 20. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA, Fiering S.
    Breast Cancer Res Treat; 2018 Sep 04; 171(2):273-282. PubMed ID: 29858752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.